中和抗體市場報告：2031 年趨勢、預測和競爭分析

全球中和抗體市場未來前景光明，醫院和診所、研究機構、診斷實驗室和製藥公司市場都存在機會。預計 2025 年至 2031 年期間全球中和抗體市場複合年成長率為 11.2%。這個市場的主要促進因素是類風濕性關節炎、多發性硬化症和紅斑性狼瘡等自體免疫疾病的發生率不斷上升，感染疾病病率不斷上升，以及人們越來越意識到抗體療法相對於傳統疫苗和藥物的益處。

• Lucintel 預測，在預測期內，治療領域仍將是最大的應用領域。
• 在最終用途類別中，製藥公司將繼續成為最大的細分市場。
• 根據地區分類，由於主要參與者的存在和遍布全國的強大的醫療保健系統，預計北美將在預測期內繼續成為最大的地區。

中和抗體市場的策略性成長機會

中和抗體市場的策略性成長受到其在各個治療領域的應用的推動。公司看到了感染疾病、腫瘤學和個人化醫療領域的巨大成長機會，以擴大其市場佔有率。

• 感染疾病治療：感染疾病尤其是新冠肺炎的增多，為中和抗體創造了巨大的成長機會。公司正致力於快速核准和大規模生產抗體以滿足全球需求。
• 腫瘤學：腫瘤學仍然是中和抗體和標靶治療療法的主要成長領域，這些療法為難以治療的癌症患者提供了有希望的治療方法。能夠選擇性攻擊癌細胞的抗體的發展是一個主要驅動力。
• 自體免疫疾病：中和抗體擴大被應用於治療自體免疫疾病，提供標靶治療，以最大限度地減少副作用並改善患者的治療效果。
• 慢性疾病：中和抗體在糖尿病和心血管疾病等慢性疾病中的使用正在增加，為改善長期健康結果提供了新的治療選擇。
• 個人化醫療：個人化醫療的進步為開發針對個別患者基因特徵的中和抗體創造了機會，從而提高了一系列疾病治療的精準度和療效。

這些策略性成長機會推動了創新並擴大了中和抗體在多個治療領域的使用，為市場持續擴張奠定了基礎。

中和抗體市場促進因素與挑戰

中和抗體市場受到技術進步、監管狀況和經濟狀況等多種因素的影響。這些市場促進因素和挑戰將在塑造市場未來成長軌跡方面發揮關鍵作用。

推動中和抗體市場的因素包括：

• 對 COVID-19 治療的需求不斷成長：全球大流行刺激了對中和抗體的需求，特別是對 COVID-19 治療的需求，從而導致研究增加和監管核准加快。
• 生物技術的進步：生物技術的不斷進步使得更有效、更有針對性的中和抗體的開發成為可能，從而推動了市場的成長。
• 腫瘤學：中和抗體在癌症治療中的廣泛應用是一個主要促進因素，良好的臨床結果帶來了新的核准和市場擴張。
• 政府支持和資金：政府正在增加對抗體研究的資助，特別是在感染疾病和腫瘤學領域，從而促進研發並加速市場成長。
• 合作夥伴關係：製藥公司和研究機構之間的合作促進了新型抗體療法的快速開發和商業化。

中和抗體市場面臨的挑戰如下：

• 開發成本高：開發中和抗體需要大量的研發和臨床試驗投入，這對中小企業來說是一個挑戰。
• 監管障礙：生物製藥複雜的監管環境可能會延遲產品核可，影響新型療法的上市時間。
• 製造複雜性：生產中和抗體是一個複雜的過程，擴大生產規模是一項挑戰，尤其是在新興市場。

中和抗體市場受到技術進步、政府支持和對新型療法的不斷成長的需求的推動。然而，在市場充分發揮其潛力之前，需要解決高開發成本和監管障礙等挑戰。

目錄

第1章執行摘要

第 2 章全球中和抗體市場：市場動態

• 簡介、背景和分類
• 供應鏈
• 產業促進因素與挑戰

第 3 章 2019 年至 2031 年的市場趨勢與預測分析

• 宏觀經濟趨勢（2019-2024）與預測（2025-2031）
• 全球中和抗體市場趨勢（2019-2024）及預測（2025-2031）
• 全球中和抗體市場（按目標病毒）
  • SARS-CoV-2
  • HIV
  • 流感
  • 伊波拉
  • 茲卡熱
  • C型肝炎
• 全球中和抗體市場（以抗體類型分類）
  • 單株抗體
  • 多株抗體
• 全球中和抗體市場（按應用分類）
  • 治療
  • 診斷
  • 研究與開發
  • 其他
• 全球中和抗體市場（依最終用途分類）
  • 醫院和診所
  • 研究組織
  • 診斷實驗室
  • 製藥公司
  • 其他

第 4 章 2019 年至 2031 年各地區的市場趨勢與預測分析

• 全球中和抗體市場（按地區）
• 北美中和抗體市場
• 歐洲中和抗體市場
• 亞太地區中和抗體市場
• 其他地區的中和抗體市場

第5章 競爭分析

• 產品系列分析
• 業務整合
• 波特五力分析

第6章 成長機會與策略分析

• 成長機會分析
  • 全球中和抗體市場成長機會（按目標病毒）
  • 全球中和抗體市場按抗體類型分類的成長機會
  • 全球中和抗體市場成長機會（按應用分類）
  • 全球中和抗體市場成長機會（依最終用途分類）
  • 全球中和抗體市場成長機會（按地區分類）
• 全球中和抗體市場的新趨勢
• 戰略分析
  • 新產品開發
  • 全球中和抗體市場產能擴大
  • 全球中和抗體市場的合併、收購和合資企業
  • 認證和許可

第7章主要企業簡介

• Regeneron Pharmaceuticals
• Eli Lilly and Company
• AstraZeneca
• GlaxoSmithKline
• Sanofi
• Roche
• Novartis
• Merck
• Pfizer
• Johnson & Johnson

The future of the global neutralizing antibody market looks promising with opportunities in the hospital and clinic, research institute, diagnostic laboratory, and pharmaceutical company markets. The global neutralizing antibody market is expected to grow with a CAGR of 11.2% from 2025 to 2031. The major drivers for this market are the growing incidence of autoimmune disorders, including rheumatoid arthritis, multiple sclerosis, and lupus, the rising prevalence of infectious diseases, and the increasing awareness of the benefits of antibody-based therapies compared to traditional vaccines and drugs.

• Lucintel forecasts that, within the application category, the therapeutic segment will remain the largest segment over the forecast period.
• Within the end-use category, pharmaceutical companies will remain the largest segment.
• In terms of regions, North America will remain the largest region over the forecast period due to the presence of major firms and a robust healthcare system across the country.

Gain valuable insights for your business decisions with our comprehensive 150+ page report.

Emerging Trends in the Neutralizing Antibody Market

The neutralizing antibody market is transforming due to technological innovations and a shift in healthcare priorities. These emerging trends are reshaping how companies develop and commercialize neutralizing antibody therapies globally.

• Increased Focus on COVID-19 Antibodies: With the global pandemic, there has been a surge in research for neutralizing antibodies targeting COVID-19. Companies are fast-tracking clinical trials and securing emergency use authorizations, making this a dominant trend in the market.
• Expansion in Oncology Treatments: Neutralizing antibodies are being increasingly utilized in oncology treatments. Companies are developing targeted therapies that attack specific cancer cells, offering more effective and less toxic treatment options.
• Personalized Medicine: The move toward personalized medicine is driving the development of antibodies tailored to individual patients' needs, particularly in cancer and autoimmune disorders. This trend enhances treatment efficacy and reduces side effects.
• Collaborations and Partnerships: The industry is seeing a rise in collaborations between biotech firms, pharmaceutical companies, and research institutions. These partnerships are speeding up innovation and enabling broader market access for new therapies.
• Technological Advancements in Biologics: Advancements in biologics manufacturing, including the use of cell-based and gene-editing technologies, are improving the efficiency and scalability of neutralizing antibody production, lowering costs, and boosting supply.

These trends are reshaping the neutralizing antibody market, with a focus on innovation, personalized treatments, and strategic collaborations, leading to more effective therapies and broader market penetration.

Recent Developments in the Neutralizing Antibody Market

The neutralizing antibody market has seen major advancements across various therapeutic areas, with key developments driving growth. Companies are focusing on innovation, partnerships, and regulatory milestones to capitalize on emerging opportunities in this fast-evolving market.

• COVID-19 Antibody Approvals: Several neutralizing antibodies have received emergency use authorizations for COVID-19 treatment, with major pharmaceutical companies launching new products that show efficacy in reducing viral loads.
• Oncology Innovations: Breakthroughs in neutralizing antibodies for oncology have been achieved, with new therapies targeting specific cancer cells, showing high effectiveness in clinical trials and receiving regulatory approvals in major markets.
• Collaborative Research Initiatives: There has been an increase in collaborative initiatives between biotech companies and academic institutions, particularly in the U.S. and Europe, aimed at accelerating antibody research for infectious diseases and cancers.
• Technological Advances in Manufacturing: Advances in biologics manufacturing have reduced production costs and improved scalability, making neutralizing antibodies more accessible and affordable for a wider range of treatments.
• Government Support for Biotechnology: Governments worldwide are increasing funding and support for biotechnology research, driving growth in the neutralizing antibody market as companies receive grants and tax incentives for R&D.

These developments are significantly impacting the neutralizing antibody market, fostering innovation, improving treatment outcomes, and enabling companies to capture new market opportunities globally.

Strategic Growth Opportunities for Neutralizing Antibody Market

Strategic growth in the neutralizing antibody market is being driven by its applications across various therapeutic areas. Companies are identifying key growth opportunities in infectious diseases, oncology, and personalized medicine, allowing them to expand their market presence.

• Infectious Disease Treatments: The rise of infectious diseases, particularly COVID-19, has created immense growth opportunities for neutralizing antibodies. Companies are focusing on fast-tracked approvals and large-scale production of antibodies to meet global demand.
• Oncology: Oncology remains a major growth area for neutralizing antibodies, with targeted therapies offering promising outcomes for patients with difficult-to-treat cancers. The development of antibodies that can selectively attack cancer cells is a key growth driver.
• Autoimmune Diseases: Neutralizing antibodies are increasingly being used in the treatment of autoimmune diseases, providing targeted therapies that minimize side effects and improve patient outcomes.
• Chronic Diseases: The use of neutralizing antibodies in chronic diseases, such as diabetes and cardiovascular conditions, is growing, offering new treatment options that improve long-term health outcomes.
• Personalized Medicine: Advances in personalized medicine are creating growth opportunities for neutralizing antibodies tailored to individual patients' genetic profiles, enhancing the precision and efficacy of treatments across various diseases.

These strategic growth opportunities are driving innovation and expanding the use of neutralizing antibodies across diverse therapeutic areas, positioning the market for continued expansion.

Neutralizing Antibody Market Driver and Challenges

The neutralizing antibody market is influenced by a variety of factors, including technological advancements, regulatory landscapes, and economic conditions. These drivers and challenges play a crucial role in shaping the market's future growth trajectory.

The factors responsible for driving the neutralizing antibody market include:

• Rising Demand for COVID-19 Therapies: The global pandemic has fueled demand for neutralizing antibodies, particularly for COVID-19 treatments, leading to increased research and rapid regulatory approvals.
• Advancements in Biotechnology: Continuous advancements in biotechnology are enabling the development of more effective and targeted neutralizing antibodies, driving market growth.
• Oncology Therapies: The expanding use of neutralizing antibodies in oncology is a major driver, with promising clinical results leading to new approvals and market expansion.
• Government Support and Funding: Governments are increasing funding for antibody research, particularly in infectious diseases and oncology, boosting R&D efforts and accelerating market growth.
• Collaborative Partnerships: Collaborations between pharmaceutical companies and research institutions are enabling faster development and commercialization of new antibody therapies.

Challenges in the neutralizing antibody market are:

• High Development Costs: The development of neutralizing antibodies requires significant investment in R&D and clinical trials, posing a challenge for smaller companies.
• Regulatory Hurdles: Navigating the complex regulatory landscape for biologics can slow down product approvals, impacting time-to-market for new therapies.
• Manufacturing Complexity: The production of neutralizing antibodies involves complex processes, making scaling up manufacturing a challenge, particularly in emerging markets.

The neutralizing antibody market is driven by technological advancements, government support, and rising demand for novel therapies. However, challenges such as high development costs and regulatory hurdles must be addressed for the market to reach its full potential.

List of Neutralizing Antibody Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. Through these strategies neutralizing antibody companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the neutralizing antibody companies profiled in this report include-

• Regeneron Pharmaceuticals
• Eli Lilly and Company
• AstraZeneca
• GlaxoSmithKline
• Sanofi
• Roche
• Novartis
• Merck
• Pfizer
• Johnson & Johnson

Neutralizing Antibody by Segment

The study includes a forecast for the global neutralizing antibody market by target virus, antibody type, application, end use, and region.

Neutralizing Antibody Market by Target Virus [Analysis by Value from 2019 to 2031]:

• SARS-CoV-2
• HIV
• Influenza
• Ebola
• Zika
• Hepatitis C

Neutralizing Antibody Market by Antibody Type [Analysis by Value from 2019 to 2031]:

• Monoclonal Antibodies
• Polyclonal Antibodies

Neutralizing Antibody Market by Application [Analysis by Value from 2019 to 2031]:

• Therapeutics
• Diagnostics
• Research and Development
• Others

Neutralizing Antibody Market by End Use [Analysis by Value from 2019 to 2031]:

• Hospitals and Clinics
• Research Institutes
• Diagnostic Laboratories
• Pharmaceutical Companies
• Others

Neutralizing Antibody Market by Region [Analysis by Value from 2019 to 2031]:

• North America
• Europe
• Asia Pacific
• The Rest of the World

Country Wise Outlook for the Neutralizing Antibody Market

Major players in the market are expanding their operations and forming strategic partnerships to strengthen their positions. Below are highlights of recent developments by major neutralizing antibody producers in key regions: the USA, China, India, Japan, and Germany.

• United States: In the U.S., recent advancements in neutralizing antibody research are driven by increased investment in COVID-19 therapies. The FDA has fast-tracked approvals for several monoclonal antibodies, further boosting the market as companies focus on cancer therapies and infectious disease treatments.
• China: In China, the neutralizing antibody market is witnessing rapid growth as local biotech companies invest in R&D and clinical trials for COVID-19 antibodies. Government support for innovation in biologics is accelerating the commercialization of neutralizing antibodies across multiple therapeutic areas.
• Germany: Germany's neutralizing antibody market is driven by collaborations between academic institutions and biotech companies. The country has made significant strides in developing antibodies for oncology and infectious diseases, with a focus on personalized medicine and targeted therapies.
• India: India's neutralizing antibody market is growing due to increased efforts in biotechnology and biopharma. The country is seeing a rise in clinical trials for COVID-19 therapies and a growing focus on antibody-based treatments for autoimmune and chronic diseases.
• Japan: Japan's neutralizing antibody market is experiencing growth driven by government initiatives to advance biotechnology and biopharmaceutical research. Major pharmaceutical companies are focusing on innovative monoclonal antibody treatments for cancer and other chronic conditions, contributing to market expansion.

Features of the Global Neutralizing Antibody Market

Market Size Estimates: Neutralizing antibody market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2019 to 2024) and forecast (2025 to 2031) by various segments and regions.

Segmentation Analysis: Neutralizing antibody market size by target virus, antibody type, application, end use, and region in terms of value ($B).

Regional Analysis: Neutralizing antibody market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different target virus, antibody type, application, end use, and regions for the neutralizing antibody market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the neutralizing antibody market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

If you are looking to expand your business in this market or adjacent markets, then contact us. We have done hundreds of strategic consulting projects in market entry, opportunity screening, due diligence, supply chain analysis, M & A, and more.

This report answers following 11 key questions:

• Q.1. What are some of the most promising, high-growth opportunities for the neutralizing antibody market by target virus (SARS-CoV-2, HIV, influenza, Ebola, zika, and hepatitis C), antibody type (monoclonal antibodies and polyclonal antibodies), application (therapeutics, diagnostics, research and development, and others), end use (hospitals and clinics, research institutes, diagnostic laboratories, pharmaceutical companies, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
• Q.2. Which segments will grow at a faster pace and why?
• Q.3. Which region will grow at a faster pace and why?
• Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
• Q.5. What are the business risks and competitive threats in this market?
• Q.6. What are the emerging trends in this market and the reasons behind them?
• Q.7. What are some of the changing demands of customers in the market?
• Q.8. What are the new developments in the market? Which companies are leading these developments?
• Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
• Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
• Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Neutralizing Antibody Market : Market Dynamics

• 2.1: Introduction, Background, and Classifications
• 2.2: Supply Chain
• 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2019 to 2031

• 3.1. Macroeconomic Trends (2019-2024) and Forecast (2025-2031)
• 3.2. Global Neutralizing Antibody Market Trends (2019-2024) and Forecast (2025-2031)
• 3.3: Global Neutralizing Antibody Market by Target Virus
  • 3.3.1: SARS-CoV-2
  • 3.3.2: HIV
  • 3.3.3: Influenza
  • 3.3.4: Ebola
  • 3.3.5: Zika
  • 3.3.6: Hepatitis C
• 3.4: Global Neutralizing Antibody Market by Antibody Type
  • 3.4.1: Monoclonal Antibodies
  • 3.4.2: Polyclonal Antibodies
• 3.5: Global Neutralizing Antibody Market by Application
  • 3.5.1: Therapeutics
  • 3.5.2: Diagnostics
  • 3.5.3: Research and Development
  • 3.5.4: Others
• 3.6: Global Neutralizing Antibody Market by End Use
  • 3.6.1: Hospitals and Clinics
  • 3.6.2: Research Institutes
  • 3.6.3: Diagnostic Laboratories
  • 3.6.4: Pharmaceutical Companies
  • 3.6.5: Others

4. Market Trends and Forecast Analysis by Region from 2019 to 2031

• 4.1: Global Neutralizing Antibody Market by Region
• 4.2: North American Neutralizing Antibody Market
  • 4.2.1: North American Neutralizing Antibody Market by Application: Therapeutics, Diagnostics, Research and Development, and Others
  • 4.2.2: North American Neutralizing Antibody Market by End Use: Hospitals and Clinics, Research Institutes, Diagnostic Laboratories, Pharmaceutical Companies, and Others
• 4.3: European Neutralizing Antibody Market
  • 4.3.1: European Neutralizing Antibody Market by Application: Therapeutics, Diagnostics, Research and Development, and Others
  • 4.3.2: European Neutralizing Antibody Market by End Use: Hospitals and Clinics, Research Institutes, Diagnostic Laboratories, Pharmaceutical Companies, and Others
• 4.4: APAC Neutralizing Antibody Market
  • 4.4.1: APAC Neutralizing Antibody Market by Application: Therapeutics, Diagnostics, Research and Development, and Others
  • 4.4.2: APAC Neutralizing Antibody Market by End Use: Hospitals and Clinics, Research Institutes, Diagnostic Laboratories, Pharmaceutical Companies, and Others
• 4.5: ROW Neutralizing Antibody Market
  • 4.5.1: ROW Neutralizing Antibody Market by Application: Therapeutics, Diagnostics, Research and Development, and Others
  • 4.5.2: ROW Neutralizing Antibody Market by End Use: Hospitals and Clinics, Research Institutes, Diagnostic Laboratories, Pharmaceutical Companies, and Others

5. Competitor Analysis

• 5.1: Product Portfolio Analysis
• 5.2: Operational Integration
• 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

• 6.1: Growth Opportunity Analysis
  • 6.1.1: Growth Opportunities for the Global Neutralizing Antibody Market by Target Virus
  • 6.1.2: Growth Opportunities for the Global Neutralizing Antibody Market by Antibody Type
  • 6.1.3: Growth Opportunities for the Global Neutralizing Antibody Market by Application
  • 6.1.4: Growth Opportunities for the Global Neutralizing Antibody Market by End Use
  • 6.1.5: Growth Opportunities for the Global Neutralizing Antibody Market by Region
• 6.2: Emerging Trends in the Global Neutralizing Antibody Market
• 6.3: Strategic Analysis
  • 6.3.1: New Product Development
  • 6.3.2: Capacity Expansion of the Global Neutralizing Antibody Market
  • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Neutralizing Antibody Market
  • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

• 7.1: Regeneron Pharmaceuticals
• 7.2: Eli Lilly and Company
• 7.3: AstraZeneca
• 7.4: GlaxoSmithKline
• 7.5: Sanofi
• 7.6: Roche
• 7.7: Novartis
• 7.8: Merck
• 7.9: Pfizer
• 7.10: Johnson & Johnson